首页> 美国卫生研究院文献>ecancermedicalscience >COVID-19 and treatment with NSAIDs and corticosteroids: should we be limiting their use in the clinical setting?
【2h】

COVID-19 and treatment with NSAIDs and corticosteroids: should we be limiting their use in the clinical setting?

机译:COVID-19以及NSAID和皮质类固醇的治疗:我们是否应限制它们在临床中的使用?

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Given the current SARS-CoV-2 (COVID-19) pandemic, the availability of reliable information for clinicians and patients is paramount. There have been a number of reports stating that non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids may exacerbate symptoms in COVID-19 patients. Therefore, this review aimed to collate information available in published articles to identify any evidence behind these claims with the aim of advising clinicians on how best to treat patients. This review found no published evidence for or against the use of NSAIDs in COVID-19 patients. Meanwhile, there appeared to be some evidence that corticosteroids may be beneficial if utilised in the early acute phase of infection, however, conflicting evidence from the World Health Organisation surrounding corticosteroid use in certain viral infections means this evidence is not conclusive. Given the current availability of literature, caution should be exercised until further evidence emerges surrounding the use of NSAIDs and corticosteroids in COVID-19 patients.
机译:鉴于当前的SARS-CoV-2(COVID-19)大流行,为临床医生和患者提供可靠信息至关重要。有许多报道指出,非甾体类抗炎药(NSAID)和皮质类固醇可能会加重COVID-19患者的症状。因此,本综述旨在整理已发表文章中的可用信息,以找出这些主张背后的任何证据,以就如何最好地治疗患者方面向临床医生提供建议。该评价未发现公开的证据支持或反对在COVID-19患者中使用NSAID。同时,似乎有证据表明,如果在感染的急性早期使用皮质类固醇可能是有益的,但是,世界卫生组织关于在某些病毒感染中使用皮质类固醇的证据相互矛盾,这意味着该证据尚无定论。鉴于目前可获得的文献资料,应谨慎行事,直到围绕COVID-19患者使用NSAID和皮质类固醇激素的证据进一步出现为止。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号